4 employees
OCTIMET has licensed from Janssen Pharmaceutica, highly selective MET kinase inhibitors with clean safety profiles
2016
$12M
from 3 investors over 3 rounds
OCTIMET Oncology NV raised $12M on January 19, 2017
Investors: Omnes, FundPlus and V-Bio Ventures